Stockreport

Needham joins bull camp on CRISPR Therapeutics; shares up 2% premarket [Seeking Alpha]

CRISPR Therapeutics AG - Common Shares  (CRSP) 
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/crsp/real-time
PDF Needham initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP ) with a Buy rating and $62 (60% upside) price target citing the initiation of clinical development [Read more]